Sponsor realizes cost-savings of $10.2m per year and increases OTIF to 97%
Our client, a leading multinational pharmaceutical company with a true commitment to delivering innovative medicines and to achieving clinical excellence, approached Fisher Clinical Services with an extensive clinical trial pipeline and the need to achieve a comprehensive, fully-managed transportation strategy. This Sponsor believed that by outsourcing the transportation element of its clinical trials the company could focus on what it did best—further developing new medicines across many therapeutic areas that could make a meaningful difference to patients’ lives across the globe.
The Sponsor took time to evaluate many potential distribution partners. After an extensive period of research and evaluation, there were 3 key reasons for choosing to partner with Fisher Clinical Services:
Also driven by the desire to achieve cost and performance efficiencies across a comprehensive pipeline of many global trials across many different therapeutic areas, the Sponsor felt confident that Fisher Clinical Services would deliver
Clear communication was a key factor to this new partnership. Fisher Clinical Services would have to work closely with the Sponsor’s in‑house study management teams to report on the distribution strategies for all studies and to strive for continuous improvement on defined metrics of measurement at all times.
In order to best service this Sponsor a global cross-functional team was established by Fisher Clinical Services, solely dedicated to this Sponsor alone. This cross-functional team was founded on specialists from IT, Quality, Project Management, Engineering, Operations and Finance, with defined contact points with external logistics companies across the globe. Further strengths of this dedicated group included its access to industry-leading logistics expertise, brokerage services, Global QA, Regulatory support and local, on-the‐ ground, expertise within each region via the Fisher Clinical Services wholly-owned global footprint.
1. Facility Network: The Sponsor recognized that the Fisher Clinical Services fully-owned network of cGMP facilities strategically located across the globe was unparalleled in the industry. This network of owned facilities linked through a common IT platform and global logistics SOPs, augmented by an extensive third party depot network, would offer the Sponsor a comprehensive footprint capable of receiving, storing and distributing clinical supplies to any location across the globe.
The capacity and specialty storage and handling conditions available at the cGMP sites assured the Sponsor flexibility in servicing multiple studies with varying IMP requirements, including the capability to manage scheduled and temperature‐ controlled drugs. Fisher Clinical Services’ local, on-site labelling capabilities and the ability to locally source rescue/co-therapies and comparators differentiated Fisher Clinical Services over other potential partners.
2. Unique, innovative logistics expertise: The Fisher Clinical Services unique and innovative solution, Total Transportation Management Service, includes complete oversight of the supply chain processes required to move IMP shipments internationally and within the country of destination, including:
Fisher Clinical logistics experts worked on a dynamic model of courier selection, using the data to allow them to choose the most effective courier based upon raw performance data. The solution was built on a fixed cost model allowing the Sponsor to receive preferential standard and premium freight rates, preferential global facility and depot rates and fixed fuel surcharges which helped them predict and manage their project and department costs.
Project Management and Logistics experts
Resources were dedicated to tracking and measuring courier performance over time with the ability to provide reports and updates in real-time to the Sponsor. This type of enhanced visibility, enabled by Fisher Clinical Services proprietary
systems, allowed Sponsor teams around the world to understand the status of their shipments and to validate performance statistics based on a common set of measurements. This data driven objectivity is unique in this industry.
In addition, clear metrics were defined. The objective of this data driven approach was to maximize the On‐Time-In‐Full (OTIF) receipts and reduce the overall costs while mitigating risk across the supply chain.
Changes to original transportation strategy
One key, impactful change to the Sponsor’s transportation strategy was a new approach to courier selection. It was decided that all of the Sponsor’s shipments across all routes and regions would be analysed in detail. In addition, data collated by the Fisher Clinical Services Global Logistics Helpdesk on all global shipments would be analysed. Shipments would be monitored not only for OTIF results but also for cost of service.
This data-driven courier selection would significantly optimize cost and performance efficiencies for this Sponsor.
3. Investigator site support: The Global Logistics Helpdesk was made available 24/5 to the Sponsor’s global teams and to investigator sites across the globe, providing proactive track and trace reporting on all supplies. The level of service offered to the investigator sites was particularly high with a can-do attitude and the ability to intervene if shipments were at risk of not being delivered at the right time, to the right place and in the right conditions.
The results were phenomenal
Significant cost savings were achieved year-on‐ year. Previously the Sponsor was sending 32% of its shipments via Premium Courier. The data driven objectivity applied by Fisher Clinical Services reduced this high percentage to just 7%, which resulted in significant cost savings of circa $10.2m per year. More importantly there was no degradation in performance. In fact, the OTIF % increased from 93% to 97%, a win-win situation for the Sponsor and for patients.
Over time the Sponsor has become well-versed in the breadth of services provided by the Fisher Clinical Services extensive network of global facilities. The Sponsor has benefited from the additional services offered by Fisher Clinical Services GMP facilities strategically located across the globe—secondary packaging, labeling, IOR capability and regulatory, import/export services. In addition the Sponsor has been able to expand its reach through leveraging the Fisher Clinical Services’ footprint guaranteeing delivery to any site in the world, often in remote and challenging locations.
Meaningful KPI reporting and analysis has enabled a culture of continuous improvement amongst the Fisher Clinical Services logistics team and the Sponsor team. Now that global processes have been standardized from study initiation through to returns and destruction, the clinical trial transportation strategy is a smooth one. The Sponsor can focus on developing innovative medicines that could impact patients’ lives all over the world.